Endocrinology, Vol 127, 93-100, Copyright © 1990 by Endocrine Society

ARTICLES

In vitro and in vivo bioactivity of recombinant human follicle- stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines

AB Galway, AJ Hsueh, JL Keene, M Yamoto, BC Fauser and I Boime
Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla 92093.

Recent studies have shown that Chinese hamster ovary (CHO) cells transfected with the FSH subunit genes secrete bioactive FSH. Here, we determined the in vitro and in vivo bioactivity of recombinant FSH produced by CHO mutant cells deficient in the glycosylation enzyme N- acetylglucosamine transferase-I (NAGT-), resulting in glycoproteins with asparagine-linked (GlcNAc)2(Mannose)5 oligosaccharides, or mutant cells defective in sialic acid transport into the Golgi (ST-). In the latter, glycoproteins are secreted lacking terminal sialic acids. Determination of in vitro bioactivity, using the granulosa cell aromatase bioassay, indicated that both FSH variants are as active as FSH secreted by the wild type (WT) cells and purified pituitary FSH. Also, these normal and variant forms of FSH are equipotent in a radioligand receptor assay using rat testis membranes. However, the variant FSH molecules are more basic than the WT FSH as determined using a chromatofocusing column (pI: wild type 3.6-5.0, NAGT- greater than 7.0, ST- approximately 6.0 and greater than 7.0). Injection of immature estrogen-treated rats with WT FSH induced high aromatase activity in their granulosa cells whereas treatment with either one of the FSH variants was ineffective; the lack of in vivo activity of the FSH variants was correlated with rapid clearance of these molecules in serum. Thus, recombinant human FSH produced by cells deficient in NAGT- I or defective in sialic acid transport retains normal receptor binding and in vitro bioactivity, but exhibits minimal in vivo activity and a shortened half-life when compared to WT FSH, indicating the important role of terminal sugars for FSH action in vivo.

This article has been cited by other articles:

				A. Balen, P. Platteau, A. N. Andersen, P. Devroey, L. Helmgaard, J.-C. Arce, and for the Bravelle Ovulation Induction (BOI) Study G Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial Hum. Reprod., July 1, 2007; 22(7): 1816 - 1823. [Abstract] [Full Text] [PDF]

				T. Forges, P. Monnier-Barbarino, B. Leheup, and P. Jouvet Pathophysiology of impaired ovarian function in galactosaemia Hum. Reprod. Update, September 1, 2006; 12(5): 573 - 584. [Abstract] [Full Text] [PDF]

				N. Azzam, R. Bar-Shalom, Z. Kraiem, and F. Fares Human Thyrotropin (TSH) Variants Designed by Site-Directed Mutagenesis Block TSH Activity in Vitro and in Vivo Endocrinology, June 1, 2005; 146(6): 2845 - 2850. [Abstract] [Full Text] [PDF]

				A. Ulloa-Aguirre, C. Timossi, J. Barrios-de-Tomasi, A. Maldonado, and P. Nayudu Impact of Carbohydrate Heterogeneity in Function of Follicle-Stimulating Hormone: Studies Derived from in Vitro and in Vivo Models Biol Reprod, August 1, 2003; 69(2): 379 - 389. [Abstract] [Full Text] [PDF]

				C. Castro-Fernández, A. Olivares, D. Söderlund, J. C. López-Alvarenga, E. Zambrano, J. D. Veldhuis, A. Ulloa-Aguirre, and J. P. Méndez A Preponderance of Circulating Basic Isoforms Is Associated with Decreased Plasma Half-Life and Biological to Immunological Ratio of Gonadotropin-Releasing Hormone-Releasable Luteinizing Hormone in Obese Men J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4603 - 4610. [Abstract] [Full Text]

				M. P. Rose, R. E. Gaines Das, and A. H. Balen Definition and Measurement of Follicle Stimulating Hormone Endocr. Rev., February 1, 2000; 21(1): 5 - 22. [Abstract] [Full Text]

				M. D'Antonio, F. Borrelli, A. Datola, R. Bucci, M. Mascia, P. Polletta, D. Piscitelli, and R. Papoian Biological characterization of recombinant human follicle stimulating hormone isoforms Hum. Reprod., May 1, 1999; 14(5): 1160 - 1167. [Abstract] [Full Text] [PDF]

				M. Grossmann, B. D. Weintraub, and M. W. Szkudlinski Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and Therapeutic Implications for the Glycoprotein Hormone Family Endocr. Rev., August 1, 1997; 18(4): 476 - 501. [Abstract] [Full Text] [PDF]

				M. Grossmann, R. Wong, N. G. Teh, J. E. Tropea, J. East-Palmer, B. D. Weintraub, and M. W. Szkudlinski Expression of Biologically Active Human Thyrotropin (hTSH) in a Baculovirus System: Effect of Insect Cell Glycosylation on hTSH Activity in Vitro and in Vivo Endocrinology, January 1, 1997; 138(1): 92 - 100. [Abstract] [Full Text] [PDF]

				M. Grossmann, M. W. Szkudlinski, J. E. Tropea, L. A. Bishop, N. R. Thotakura, P. R. Schofield, and B. D. Weintraub Expression of Human Thyrotropin in Cell Lines with Different Glycosylation Patterns Combined with Mutagenesis of Specific Glycosylation Sites J. Biol. Chem., December 8, 1995; 270(49): 29378 - 29385. [Abstract] [Full Text] [PDF]